Close Menu

GenMark Diagnostics: James McNally

Jan 21, 2020

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

More Like This

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Nov 25, 2020

Enzo Biochem: Ian Walters

Ian Walters has been appointed to the board of directors of Enzo Biochem. He is the CEO and director of Portage Biotech, a biopharmaceutical firm developing immuno-oncology treatments. Previously, he was executive director of global oncology clinical research and business development at Bristol-Myers Squibb and medical director at Millennium Pharmaceuticals. Walters holds an MBA from the Wharton School of the University of Pennsylvania and an MD from Albert Einstein College of Medicine.

Nov 23, 2020

Thermo Fisher Scientific: Alexandra Keith

Alexandra Keith has been elected to the board of directors of Thermo Fisher Scientific. She is the CEO of Procter & Gamble's global beauty business and a member of P&G's global leadership council. Over the past 30 years, she has served in a variety of roles at P&G, including in manufacturing, logistics, communications, and product innovation.

Nov 20, 2020

Congenica: Sam Roberts

Sam Roberts has been appointed as a non-executive board director of Congenica. She is the managing director of Health & Care at Legal & General, which co-led Congenica's recent $50 million Series C funding round. Previously, she was the chief executive of the Accelerated Access Collaborative, an umbrella organization for UK health innovation. She also used to be director of innovation, research, and life sciences at NHS England. Roberts holds an MBA from the Australian Graduate School of Management and a doctorate in evidence-based healthcare from the University of Oxford.

Nov 20, 2020

Omniome: Robert Wicke

Omniome has appointed Robert Wicke as CEO. He is also joining the San Diego-based sequencing technology company's board of directors. Wicke comes to Omniome from Halo Labs, where he was CEO. Previously, he held executive leadership positions at ForteBio, Pall, Molecular Devices, and Axon Instruments.

Nov 19, 2020

Icahn School of Medicine at Mount Sinai: Alison Goate

Alison Goate has been named chair of the department of genetics and genomics sciences at the Icahn School of Medicine at Mount Sinai, effective Jan. 1, 2021.

Goate is the Willard T.C. Johnson research professor of neurogenetics and a professor of genetics and genomic science, neuroscience, and neurology. Her research focuses on genetic risk factors of neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia.

She came to Mount Sinai in 2015 as founding director of the Ronald M. Loeb Center for Alzheimer's Disease and is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science. Goate holds a doctorate from the University of Oxford.

Nov 19, 2020

Natera: Monica Bertagnolli

Monica Bertagnolli has been appointed to the board of directors of Natera. She is a professor of surgery at Harvard Medical School and associate surgeon in the division of surgical oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In addition, she is the CEO of Alliance Foundation Trial, a nonprofit organization that conducts international cancer clinical trials, as well as VP of the Coalition of Cancer Cooperative Groups. Bertagnolli holds an undergraduate degree in engineering from Princeton University and a medical degree from the University of Utah College of Medicine.

Nov 18, 2020

PierianDx: Mark McDonough

PierianDx has hired Mark McDonough as CEO. McDonough, who has also joined the company's board of directors, takes over from Chairman and interim CEO Joe Boorady. The previous permanent CEO, Michael Sanderson, left PierianDx in April. McDonough previously was president and CEO of immunogenomics startup Immunis.AI. He also led CombiMatrix through that firm's 2017 acquisition by Invitae.

Nov 18, 2020

Quanterix: William Geist

Quanterix has named William Geist as chief operating officer. Geist most recently served as vice president and general manager for two of Thermo Fisher Scientific's protein and cell analysis and qPCR business units. He also held a key leadership role in Thermo Fisher's COVID-19 task force in its biosciences division. Prior to this, Geist held numerous sales, marketing, and business development leadership roles including vice president of sales, marketing, and business development at Qiagen's Quanta BioSciences. He holds a BA in biology from Dartmouth College.

Nov 17, 2020

Day Zero Diagnostics: Dekel Gelbman, Robin Patel, Sally Hojvat

Day Zero Diagnostics has appointed Dekel Gelbman as senior VP of business development and strategy, Robin Patel as a member of its scientific advisory board, and Sally Hojvat as a regulatory strategy advisor.

Gelbman joins the company from FDNA, where he was the founding CEO. Before that, he was a corporate and transactional attorney in Israel and the US.

Patel is the director of the infectious diseases research laboratory and co-director of the clinical bacteriology laboratory at the Mayo Clinic.

Hojvat is a senior consultant at Partners in Diagnostics. Prior to that, she was the director of the division of microbiology devices at the Center for Devices and Radiological Health at the US Food and Drug Administration.

Nov 17, 2020

Veracyte: John Hanna, Morten Frost

Veracyte has appointed John Hanna as its general manager of endocrinology, breast cancer, and lymphoma; and Morten Frost as its general manager of pulmonology. The firm has established the general manager structure as part of its plans for global expansion.

Hanna currently serves as Veracyte's chief commercial officer. Prior to Veracyte, Frost most recently held the role of head of global marketing for pathology and companion diagnostics at Agilent Technologies.

Nov 17, 2020

Inivata: Alan Schafer

Inivata has appointed Alan Schafer as its chief technology officer. Schafer previously served as CEO of 14M Genomics, a cancer molecular diagnostic firm. Prior to 14M Genomics, he served as CEO of Population Genetics. He has also served as global VP of technology development at GlaxoSmithKline and VP of genetics at Incyte. 

Nov 17, 2020

Sophia Genetics: Bram Goorden

Sophia Genetics has hired Bram Goorden as chief commercial officer and head of North American operations. Goorden, who will oversee expansion of the firm's global reach, joins Sophia from Foundation Medicine, where he was VP of international business and partnering. He previously served as general manager and head of therapeutics for Prometheus Laboratories.

Nov 16, 2020

Inteliquet: Tandy Tipps

Inteliquet has appointed Tandy Tipps as senior vice president of healthcare organizations solutions. In this role, Tipps will focus on advancing a site-centric approach to patient matching for clinical trials and precision medicine through a combination of technology, analytics, and clinical research expertise. Tipps previously developed and led the Oncology Site Network at Precision for Medicine. She also previously served as administrative director of a Phase I clinical trial program at the University of Texas MD Anderson Cancer Center.

Nov 13, 2020

Centogene: Jonathan Sheldon

Jonathan Sheldon has been nominated as a member of the supervisory board of Centogene. He will serve as an interim member with immediate effect until his confirmation at an upcoming shareholder meeting. Sheldon is senior VP of the digital insights business area at Qiagen and has led Qiagen's Digital Insights global business since 2018. Prior to this, he was global VP at Oracle Health Sciences.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.